Top Pharmacology Researcher to Oversee School of Medicine’s Pioneering Biomedical Research

Top Pharmacology Researcher to Oversee School of Medicine’s Pioneering Biomedical Research

The University of Virginia School of Medicine has named Jeffrey R. Martens, PhD, an internationally recognized pharmacology researcher, leader, and educator, as the new Senior Associate Dean for Research. Martens will assume his new role on May 15, 2023. 

“Professor Martens will be a key contributor in the transformation of the School of Medicine and UVA Health medical research program, while also managing a rapidly growing portfolio of resources, innovative projects, and talent for the School of Medicine and the greater University,” said Melina R. Kibbe, MD, the dean of the UVA School of Medicine and chief health affairs officer for UVA Health.

Martens comes to UVA from the University of Florida College of Medicine, where he has served as chair of the Department of Pharmacology and Therapeutics for the past eight years. He has driven a 10-fold increase in outside research funding during his tenure. He also spearheaded collaboration within the College of Medicine as well as with research centers and institutes across the University of Florida. In addition, the academic and scientific achievements of his faculty resulted in U.S. News & World Report ranking for Pharmacology and Toxicology at UF in the top 17 nationally, the top nine among public universities and 50th internationally.

The impact of Martens’ research is demonstrated through his long list of peer-reviewed publications and the fact that his research has been continuously funded by the National Institutes of Health, National Science Foundation and the American Heart Association, among others, since 1990. Dr. Martens’ research is focused in two areas of pharmacology and therapeutics, including sensory neuropharmacology and cardiovascular pharmacology, with work in both the heart and olfactory systems.

Martens holds longstanding memberships in several professional societies, including the American Society for Pharmacology and Experimental Therapeutics and the Association of Chemoreception Sciences. He also has served in several editorial board positions for scientific publications, most recently as an editorial advisory board member for Molecular Pharmacology.

Martens earned his bachelor’s degree and doctorate from the University of Florida and did his post-doctoral training at Colorado State University. Before joining the faculty at the University of Florida, Martens was a faculty member at Oregon Health & Science University and the University of Michigan.

“This position at UVA is a new and different opportunity to lead across department boundaries and integrate the School of Medicine’s excellent clinical, translational and basic science efforts,” Martens said. “I am excited to collaborate with the School of Medicine’s world-class faculty and join a respected leadership team at a time of transformational growth.”

He succeeds Linda Duska, MD, MPH, who has served as interim Senior Associate Dean for Research since March 15, 2021. “The strategic guidance, leadership and program oversight Dr. Duska has provided to the School of Medicine has been invaluable,” Kibbe said. “I have extraordinary gratitude for her dedication and commitment to the School of Medicine and UVA Health.”

Duska will continue in her roles as Associate Dean for Clinical Research in the School of Medicine, Vice Chair for Research in the Department of Obstetrics and Gynecology, and as a gynecologic oncologist at the UVA Cancer Center.

WHO updates critical medicines list for radiological and nuclear emergencies

The Planet Wellness Corporation (WHO) right now up to date its record of medications that need to be stockpiled for radiological and nuclear emergencies, along with coverage advice for their appropriate administration. These stockpiles incorporate medications that both stop or minimize publicity to radiation, or address accidents the moment exposure has transpired.

“In radiation emergencies, people may well be exposed to radiation at doses ranging from negligible to daily life-threatening. Governments require to make therapies readily available for those in will need – rapid,” stated Dr Maria Neira, WHO Acting Assistant Director-Common a.i, Much healthier Populations Division. “It is critical that governments are geared up to safeguard the wellbeing of populations and respond quickly to emergencies. This incorporates possessing all set supplies of lifesaving medications that will decrease risks and handle injuries from radiation.” 

Essential highlights

  • This publication supersedes the 2007 WHO report on the development of national stockpiles for radiation emergencies. It incorporates up to date information on the stockpile formulary centered on the developments in radiation unexpected emergency medication in the past decade.
  • It supplies policy advice for acquisition of medicines which can protect against or minimize radionuclides uptake or maximize elimination of radionuclides from the human entire body.
  • It appears to be like at the major elements required for establishing, retaining and managing the national stockpiles of specific health care materials which will be demanded for radiological and nuclear emergencies. 
  • The report seems to be at the job of nationwide health authorities in stockpile growth as effectively as the position of WHO. As the primary global corporation in general public health with both the authority and responsibility to support in wellbeing emergencies, WHO delivers tips and guidance to nations around the world on community health preparedness and reaction to radiation emergencies, such as stockpile improvement. In overall health emergencies WHO may well assist in procuring or sharing healthcare materials among the countries.
  • This report features a temporary assessment of picked rising technologies and drug formulations, such as prospective repurposing of solutions previously permitted for other indications.
  • Last but not least, the publication supplies illustrations of tactics in setting up and managing a national stockpile in chosen nations, namely Argentina, Brazil, France, Germany, Japan, Republic of Korea, Russian Federation and United states.

“This current significant medications checklist will be a crucial preparedness and readiness software for our partners to establish, procure, stockpile and provide effective countermeasures in a well timed manner to all those at danger or exposed in these functions,” said Dr Mike Ryan, Government Director of WHO’s Health Emergencies Programme.

Normally, a countrywide stockpile for all-dangers health emergencies would consist of generic supplies and elements utilized for any form of emergencies, these as personalized protecting tools (PPE), trauma kits, fluids, antibiotics and painkillers. This publication features only distinct medication which are known and licensed nowadays to prevent or handle human more than-publicity to radiation.

Radiological and nuclear emergencies could end result in publicity to radiation doses significant sufficient to guide to intense health and fitness outcomes or even dying. It is therefore extremely crucial that governments respond quickly to this kind of threats. Many international locations, on the other hand, continue to lack the important factors of preparedness for radiation emergencies, in accordance to yearly reporting to the WHO Secretariat.

Likely situations considered in the publication involve radiological or nuclear emergencies at nuclear electricity vegetation, health care or study facilities, or accidents in the course of transport of radioactive components, as nicely as intentional employs of radioactive components with malicious intent.

Parts of a pharmaceutical stockpile for radiation emergencies

This publication focuses on pharmaceuticals for dealing with radiation exposure and addresses the governance and management of this sort of a stockpile. A common radiation emergency stockpile will involve the subsequent medicines:

  • Steady iodine, administered to avert or cut down the publicity of the thyroid to radioactive iodine
  • Chelating sand decorporating agents (Prussian blue, used to take out radioactive caesium from the overall body and calcium- / zinc-DTPA used to deal with inner contamination with transuranium radionuclides)
  • Cytokines utilised for mitigation of harm to the bone marrow, in situation of acute radiation syndrome (ARS) and
  • Other medications employed to take care of vomiting, diarrhoea and bacterial infections.

Rising remedies and countermeasures also reviewed in the report give perception to the foreseeable future clinical countermeasures that could be made use of for managing patients overexposed to radiation. In distinct, reports pinpointing new cellular and molecular pathways and signifies of administrating drugs could be exploited for novel remedies and new goods for use all through a radiation emergency.

Unexpected emergency preparedness, reaction and restoration will save lives

Coordination of regional, nationwide and international responses is vital for a harmonized reaction to radiation emergencies. As the company responsible for guiding healthcare interventions globally, WHO offers information and assures obtain to medications and wellbeing products and services for nations around the world that are developing countrywide capacity for preparedness and reaction to radiation emergencies. 

Extra facts

WHO’s worldwide pro community, REMPAN

WHO’s world wide specialist network, REMPAN (Radiation Unexpected emergency Professional medical Preparedness and Aid Community), is an crucial asset of the Group for implementing its perform on giving technological direction and tools for response, delivering activities for setting up potential via training and training, and on marketing international cooperation and details-sharing involving the associates of the network and the specialist neighborhood in the industry of radiation emergency medication.

WHO is a member of ICARNE, the Inter-Agency Committee on Radiological and Nuclear Emergencies, which supplies the coordination mechanism in between 20 intercontinental organizations with appropriate mandates. Customers of IACRNE develop, preserve and co-sponsor the Joint Radiation Unexpected emergency Management Program of the Global Businesses (JPlan 2017). The JPlan describes a common knowing of just about every organization’s roles in earning preparedness arrangements and through a reaction and recovery.